# **IRB Policies on Clinical Trials during COVID-19**

03-20-20 • alert • katherine leibowitz

# Here are links to examples of IRB policies on how COVID-19 is affecting clinical trials at research institutions.

This list accompanies our post on the <u>Impact of COVID-19 on Clinical Trials</u>. The list is provided for your convenience and is not based on where our clients are sponsoring clinical studies (although we have negotiated with many of these sites).

**UCLA Clinical and Translational Science Institute:** 

COVID-19 - Updates March 2020

MedStar Health Research Institute:

**Research Activities During COVID-19** 

**NYU Update:** 

Research Operations During COVID19

**Duke University Research:** 

Coronavirus (COVID-19) Research-Related Updates

Johns Hopkins Institutional Review Board:



# COVID-19 FAQs

# **Columbia University Research:**

COVID-19 (Novel Coronavirus): FAQs Relating to Research

**Northwestern University IRB:** 

IRB Office COVID-19 Memo to Research Community

**Emory University Office of Research Administration:** 

Research Guidance During COVID-19

**University of Michigan:** 

**COVID-19 Research Operations** 

University of Michigan:

COVID-19 Guidance for the Research Community

**Baylor University:** 

**COVID-19 Research Update** 





**Boston University Medical Campus and Boston Medical Center IRB:** 

FAQs: Impact of COVID-19 on Human Subjects Research

DF/HCC Dana Farber/Harvard Cancer Center:

Update on Potential Protocol Deviations and Violations Related to COVID-19 Precautions

University of Texas at Austin at Austin:

COVID-19 Considerations for Human Subject Research

UC Davis Office of Research:

Research Continuity & Planning for COVID-19

**University of Washington Research:** 

**COVID-19 and Human Subjects Research** 

USC University of Southern California Office for the Protection of Research Subjects:

COVID-19 FDA Guidance

UT Southwestern Medical Center:

Impact of COVID-19 on Researchers

© 2024 Leibowitz Law. All rights reserved. "Leibowitz Law" is a trade name of Leibowitz LLC.



#### **Penn State:**

COVID-19: Human Subjects

**University of Pittsburgh HRPO:** 

COVID-19 (Coronavirus)

#### Boston Children's Hospital/Harvard Medical School Teaching Hospital:

**IRB New COVID-19** 

University of North Carolina at Chapel Hill:

Office of the Vice Chancellor for Research Responds to COVID-19 (Updated 3/24/2020)

### **Ohio State University Office of Research Practices:**

Interim Ohio State Guidance and FAQs on Human Subjects-Related Research Visits During COVID-19 Outbreak

# **Pennington Biomedical Research Center:**

Memo: COVID-19 Study Related Issues: This memo applies only to COVID-19 related issues resulting in a deviation from the protocol.



If you have any questions or would like more information about these developing issues, please contact the following:

KATHERINE LEIBOWITZ 1-610-896-5788 Katherine.Leibowitz@LeibowitzLawTeam.com

The contents of this post should not be construed as legal advice or a legal opinion on any specific facts or circumstances. This content is not intended to and does not, by its receipt, create an attorney-client relationship. The contents are intended for general informational purposes only. We urge you to consult your attorney about the specific situation and any legal questions you may have. Attorney advertising in some jurisdictions. © 2023 Leibowitz Law. All rights reserved. "Leibowitz Law" is a trade name of Leibowitz LLC.